Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Merus N.V. (MRUS : NSDQ)
 
 • Company Description   
Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

Number of Employees: 175

 
 • Price / Volume Information   
Yesterday's Closing Price: $16.80 Daily Weekly Monthly
20 Day Moving Average: 325,349 shares
Shares Outstanding: 43.55 (millions)
Market Capitalization: $731.64 (millions)
Beta: 1.11
52 Week High: $33.09
52 Week Low: $14.78
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.97% -17.84%
12 Week -37.24% -29.47%
Year To Date -47.17% -35.46%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
YALELAAN 62
-
UTRECHT,P7 3584
NLD
ph: 31-0-30-253-8800
fax: -
enquiries@merus.nl http://www.merus.nl
 
 • General Corporate Information   
Officers
Sven (Bill) Ante Lundberg - President; Chief Executive Officer and Principal
Anand Mehra - Chairman of the Board of Directors
Harry Shuman - Chief Accounting Officer
Mark T. Iwicki - Director
Len Kanavy - Director

Peer Information
Merus N.V. (CORR.)
Merus N.V. (RSPI)
Merus N.V. (CGXP)
Merus N.V. (BGEN)
Merus N.V. (GTBP)
Merus N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N5749R100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 43.55
Most Recent Split Date: (:1)
Beta: 1.11
Market Capitalization: $731.64 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.48 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.46
Price/Cash Flow: -
Price / Sales: 13.96
EPS Growth
vs. Year Ago Period: -53.57%
vs. Previous Quarter: -26.47%
Sales Growth
vs. Year Ago Period: 39.58%
vs. Previous Quarter: -20.76%
ROE
03/31/22 - -29.02
12/31/21 - -27.26
09/30/21 - -39.37
ROA
03/31/22 - -18.73
12/31/21 - -16.76
09/30/21 - -22.03
Current Ratio
03/31/22 - 6.17
12/31/21 - 5.90
09/30/21 - 4.47
Quick Ratio
03/31/22 - 6.17
12/31/21 - 5.90
09/30/21 - 4.47
Operating Margin
03/31/22 - -143.77
12/31/21 - -135.65
09/30/21 - -173.15
Net Margin
03/31/22 - -143.77
12/31/21 - -135.65
09/30/21 - -185.10
Pre-Tax Margin
03/31/22 - -143.58
12/31/21 - -135.57
09/30/21 - -184.41
Book Value
03/31/22 - 6.83
12/31/21 - 8.15
09/30/21 - 5.30
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©